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Background: Metabolic syndrome (MS) is a known risk factor for native coronary artery disease. Its effect on patency of coronary artery bypass 
grafts (CABG) is not clear. We studied the long-term effect of MS on patients with saphenous vein grafts (SVG) and internal mammary artery grafts 
(IMAG).
Methods: We investigated 1,000 consecutive patients (mean age 66 years, 66% men) who underwent CABG surgery from Jan. 2000 to Aug. 2004. 
Of those, 517 patients had MS and 483 did not. Patients were followed until Oct. 2011 or until repeat surgery with coronary angiography due to 
angina, abnormal stress test, STEMI or NSTEMI. Atherosclerosis of bypass grafts was classified as patent (0%), mild (<50%), moderate (50-70%), 
severe (71-99%) or occluded (100%). Wilcoxon rank sum and chi-square/Fisher’s exact tests were used to analyze data.
Results: Failure of SVG was more prominent in patients with MS (Table). There was no difference in disease severity of IMAG in both groups 
(p>0.05). MS patients required more SVG placement in surgery (1.7 vs. 1.5, p=0.005) and more repeat percutaneous coronary interventions of 
their SVG (81% vs. 19%, p<0.001) than those without MS. There was no difference in time to presentation to first follow-up angiogram, time to first 
occluded SVG or first occluded IMAG, number of follow-up angiograms, repeat CABG or all-cause mortality (all p>0.05).
Conclusions: Saphenous vein graft disease is inversely related to metabolic syndrome. Incidence of percutaneous interventions is higher in 
patients with MS.
